Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide

Endocrine Practice

Volumn 18, Issue 2, 2012, Pages 227-237

  Pencek, Richard ^a   Brunell, Steven C ^a   Li, Yan ^a   Hoogwerf, Byron J ^b   Malone, James ^b  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; SULFONYLUREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BODY WEIGHT; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIPID BLOOD LEVEL; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT REDUCTION;

ADULT; AGED; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOMS; WEIGHT LOSS;

EID: 84859879074     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11306.OR     Document Type: Article

References (29)

1. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-3723.
2. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3-19.
3. Kruger DF, Martin CL, Sadler CE. New insights into glucose regulation. Diabetes Educ. 2006;32:221-228.
4. Nathan DM, Buse JB, Davidson MB, et al (American Diabetes Association; European Association for the Study of Diabetes). Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy; a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
5. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control [correction appears in Endocr Pract. 2009;15:768-770]. Endocr Pract. 2009;15:540-559.
6. Byetta (exenatide) injection [prescribing information]. San Diego, CA: Amylin Pharmaceuticals Inc, 2011.
7. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD (Exenatide-113 Clinical Study Group). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
8. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28: 1092-1100.
9. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG (GWAA Study Group). Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med. 2005; 143:559-569.
10. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
11. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333-2348.
12. Zinman B, Hoogwerf BJ, Durán García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial [published correction appears in Ann Intern Med. 2007;146:896]. Ann Intern Med. 2007;146:477-485.
13. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study [published correction appears in Clin Ther. 2008;30:1937]. Clin Ther. 2008;30:1448-1460.
14. Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: Results of Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009;11:1153-1162.
15. Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract. 2009;83:69-76.
16. Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J. 2009;56:415-424.
17. Apovian CM, Bergenstal RM, Cuddihy RM, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010;123:468.e9-468.e17.
18. Liutkus J, Rosas Guzman J, Norwood P, et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab. 2010;12:1058-1065.
19. DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010;33:951-957.
20. Gallwitz B, Böhmer M, Segiet T, et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: A randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care. 2011;34:604-606.
21. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9:6.
22. Kadowaki T, Namba M, Imaoka T, et al. Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Invest. 2011;2:210-217.
23. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med. 2011;154:103-112.
24. DeFronzo RA. Banting Lecture: From the triumvirate to the ominous octet; a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
25. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008; 57:1340-1348.
26. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
27. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: A randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167-174.
28. Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther. 2010;12:491-501.
29. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24:758-767.